GXLV:LSE:LSE-SPDR® S&P® U.S. Health Care Select Sector UCITS ETF GBP (GBP)

ETF | Others |

Last Closing

USD 33.42

Change

-0.05 (-0.13)%

Market Cap

N/A

Volume

2.33K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

+0.50 (+0.22%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+4.04 (+3.05%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.12 (-0.70%)

USD 562.96B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.27%)

USD 562.96B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-1.05 (-1.67%)

USD 266.08B
0QZO:LSE 0QZO

-1.20 (-1.07%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.20 (-0.70%)

USD 211.57B
0QZ3:LSE Qualcomm Inc.

+5.94 (+3.92%)

USD 202.26B
0R24:LSE Intel Corp.

+0.54 (+2.74%)

USD 196.14B

ETFs Containing GXLV:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.82% 45% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.82% 40% F 48% F
Trailing 12 Months  
Capital Gain 5.15% 47% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.15% 43% F 51% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.62% 39% F 48% F
Dividend Return 3.62% 38% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.16% 58% F 74% C
Risk Adjusted Return 29.80% 43% F 58% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.